Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: alzheimeruncontrolledscoredementiadonepezil
  Phrases that lowered it: participantsopen labeltrial toevaluaterandomized open
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 6 (lowers risk) · Design
• Sponsor's past termination rate: 7.1% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 51 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Minimum age: 45 (lowers risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 14.6% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: 90 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 2 (raises risk) · Design
• Sponsor's past trials: 84 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease NCT01539031 · started 2012 · scored riskier than 64% of active trials completed
• Study to Evaluate DNL747 in Subjects With Alzheimer's Disease NCT03757325 · started 2019 · scored riskier than 44% of active trials completed
• Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA) NCT03055741 · started 2016 · scored riskier than 27% of active trials completed
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease NCT01404169 · started 2011 · scored riskier than 84% of active trials completed
• Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors NCT01549834 · started 2012 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.